GLAXF - GlaxoSmithKline: Solid Prospects In The Vaccine Race

GlaxoSmithKline plc (NYSE:GSK) has bounced back nicely after COVID-19 sell-off, though over 3 years, still underperformed most peers.

Data by YCharts

Thanks to COVID-19, the company delivered solid Q1 results, but the 2020 guidance was confirmed as we should expect reversals in the next few quarters. Even though 2020 is still expected to be a down year (in terms of EPS growth), we like GSK, due to some real near-term catalysts, high dividend yield, and attractive valuation especially considering long-term prospects.

Comments cited below are from GSK Q1 Press Release, GSK Q1

Read more ...